Sirolimus goes under the microscope

Article

MacuSight has initiated a phase I study of its proprietary formulation of sirolimus to evaluate its safety and efficacy as a treatment for wet age-related macular degeneration (AMD).

MacuSight has initiated a phase I study of its proprietary formulation of sirolimus to evaluate its safety and efficacy as a treatment for wet age-related macular degeneration (AMD).

The randomized, open-label, dose escalation trial will enrol 30 patients to receive a single injection of sirolimus. There are to be six treatment arms with patients receiving one of three doses of the formulation via a subconjunctival injection or one of three doses via intravitreal injection.

Sirolimus is a broad-acting compound that is able to combat disease through multiple mechanisms of action including anti-angiogenesis, immunosuppression, anti-migration, anti-proliferation, anti-fibrosis and anti-permeability.

MacuSight recently initiated a similar phase I trial of the formulation in patients with diabetic macular oedema.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.